source
- Novartis halts Phase 2 lupus nephritis trial of Fabhalta, cites strategic reasonsNovartis has stopped a Phase 2 study of its complement blocker Fabhalta (iptacopan) in patients with lupus nephritis, a kidney involving form of the disease. The company said the decision was base…
- Early CDMO engagement: balancing speed with flexibility in CMC planningBringing a new therapy to the clinic requires clinical, non‑clinical, regulatory and CMC activities to move forward together. In early development, having drug material available is often on the cr…